TY  - RPRT
TI  - A phase I clinical study of the safety, tolerability, pharmacokinetics and pharmacodynamics of SHR-2106, an anti-CD40 antibody, following single intravenous or subcutaneous administration in healthy participants.
AU  - Jie Huang
AU  - Qiang-da Huang
AU  - Jin-Lian Xie
AU  - Qian Wu
AU  - Kun-Hong Deng
AU  - Shuang Yang
AU  - Xiao-Yan Yang
AU  - Ying Wang
AU  - Ying Zhu
AU  - Qiuna Du
AU  - Chuanpin Chen
AU  - Guo-Ping Yang
PY  - 2026
DO  - 10.1016/j.ejphar.2026.179291
UR  - https://pubmed.ncbi.nlm.nih.gov/42648529/
ID  - 42648529
ER  -